肺炎球菌蛋白疫苗与13价肺炎球菌结合疫苗联合接种预防幼儿急性中耳炎的效力、安全性和免疫原性:一项IIb期随机研究
在6-12周龄美洲原住民婴儿中开展的IIb期双盲对照试验,1803名婴儿随机1:1接受dPly/PhtD蛋白疫苗或安慰剂,与PCV13同时接种。对AAP定义急性中耳炎的疫苗效力为3.8%(95%CI:-11.4,16.9),未证明在PCV13基础上额外预防急性中耳炎的效力;疫苗有免疫原性且耐受性良好。
要点
- dPly/PhtD疫苗与PCV13联用未证明对AAP定义急性中耳炎有额外效力(VE 3.8%,95%CI -11.4~16.9)。
- 对其它中耳炎和急性下呼吸道感染结局的效力点估计均较低且置信区间包含零。
- dPly/PhtD疫苗在美洲原住民婴儿中有免疫原性,安全性和反应原性可接受。
核心结论
- dPly/PhtD疫苗有免疫原性且耐受性良好,但未证明在PCV13基础上对AAP定义急性中耳炎有额外效力。
研究设计与样本
- IIb期双盲对照试验,纳入6-12周龄美洲原住民婴儿1803名,随机1:1接受dPly/PhtD疫苗(900名)或安慰剂(903名)。
- dPly/PhtD疫苗含肺炎球菌溶血素类毒素dPly 10 µg和肺炎球菌组氨酸三聚体蛋白D PhtD 10 µg,在2、4、6、12-15月龄与PCV13同时接种,其它儿科疫苗按常规免疫程序接种。
- 在亚队列中评估免疫原性、反应原性和非 solicited 不良事件,在所有儿童中评估严重不良事件。
主要发现
- 对AAP定义急性中耳炎全部发作的疫苗效力为3.8%(95%CI:-11.4,16.9)。
- 对其它急性中耳炎结局的疫苗效力点估计范围为2.9%(-9.5,14.0)至5.2%(-8.0,16.8)。
- 对急性下呼吸道感染结局的疫苗效力点估计范围为-4.4%(-39.2,21.8)至2.0%(-18.3,18.8)。
- 对首次发作的疫苗效力点估计倾向于高于全部发作,但置信区间包含零。
- dPly/PhtD疫苗在美洲原住民婴儿基础免疫和加强免疫后有免疫原性,反应原性和安全性可接受。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Native American populations experience a substantial burden of pneumococcal disease despite use of highly effective pneumococcal conjugate vaccines (PCVs). Protein-based pneumococcal vaccines may extend protection beyond the serotype-specific protection elicited by PCVs. METHODS: In this phase IIb, double-blind, controlled trial, 6-12 weeks-old Native American infants randomized 1:1, received either a protein-based pneumococcal vaccine (dPly/PhtD) containing pneumolysin toxoid (dPly, 10 µg) and pneumococcal histidine triad protein D (PhtD, 10 µg) or placebo, administered along with 13-valent PCV (PCV13) at ages 2, 4, 6 and 12-15 months. Other pediatric vaccines were given per the routine immunization schedule. We assessed vaccine efficacy (VE) against acute otitis media (AOM) and acute lower respiratory tract infection (ALRI) endpoints. Immunogenicity, reactogenicity and unsolicited adverse events were assessed in a sub-cohort and serious adverse events were assessed in all children. RESULTS: 1803 infants were randomized (900 dPly/PhtD; 903 Control). VE against all episodes of American Academy of Pediatrics (AAP)-defined AOM was 3.8% (95% confidence interval: -11.4, 16.9). Point estimates of VE against other AOM outcomes ranged between 2.9% (-9.5, 14.0) and 5.2% (-8.0, 16.8). Point estimates of VE against ALRI outcomes ranged between -4.4% (-39.2, 21.8) and 2.0% (-18.3, 18.8). Point estimates of VE tended to be higher against first than all episodes but the confidence intervals included zero. dPly/PhtD vaccine was immunogenic and had an acceptable reactogenicity and safety profile after primary and booster vaccination in Native American infants. CONCLUSIONS: The dPly/PhtD vaccine was immunogenic and well tolerated, however, incremental efficacy in preventing AAP-AOM over PCV13 was not demonstrated. CLINICAL TRIALS REGISTRATION: NCT01545375 (www.clinicaltrials.gov).
引用
- Hammitt LL, Campbell JC, Borys D, et al. Efficacy, safety and immunogenicity of a pneumococcal protein-based vaccine co-administered with 13-valent pneumococcal conjugate vaccine against acute otitis media in young children: A phase IIb randomized study. Vaccine. 2019. PMID: 31629570. doi:10.1016/j.vaccine.2019.09.076
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。